JP2016528246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528246A5 JP2016528246A5 JP2016533973A JP2016533973A JP2016528246A5 JP 2016528246 A5 JP2016528246 A5 JP 2016528246A5 JP 2016533973 A JP2016533973 A JP 2016533973A JP 2016533973 A JP2016533973 A JP 2016533973A JP 2016528246 A5 JP2016528246 A5 JP 2016528246A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- represented
- combination
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims description 95
- 150000003839 salts Chemical class 0.000 claims description 44
- 239000003795 chemical substances by application Substances 0.000 claims description 39
- 229940079593 drug Drugs 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 32
- 229960003881 letrozole Drugs 0.000 claims description 12
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical group C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 12
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 11
- 229960002258 fulvestrant Drugs 0.000 claims description 11
- 229940122815 Aromatase inhibitor Drugs 0.000 claims description 10
- 239000013059 antihormonal agent Substances 0.000 claims description 10
- 239000003886 aromatase inhibitor Substances 0.000 claims description 10
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims description 8
- NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 claims description 8
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims description 6
- 239000012828 PI3K inhibitor Substances 0.000 claims description 6
- 108091007960 PI3Ks Proteins 0.000 claims description 6
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims description 6
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 6
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims description 6
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims description 6
- 230000037361 pathway Effects 0.000 claims description 6
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 6
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 5
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 5
- 229960005167 everolimus Drugs 0.000 claims description 5
- 229960000255 exemestane Drugs 0.000 claims description 5
- 229940102550 Estrogen receptor antagonist Drugs 0.000 claims description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 4
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 4
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims description 4
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims description 4
- 230000003637 steroidlike Effects 0.000 claims description 4
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- 229940000425 combination drug Drugs 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 7
- 208000003200 Adenoma Diseases 0.000 description 2
- 206010001233 Adenoma benign Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361865804P | 2013-08-14 | 2013-08-14 | |
| US61/865,804 | 2013-08-14 | ||
| US201361894029P | 2013-10-22 | 2013-10-22 | |
| US61/894,029 | 2013-10-22 | ||
| PCT/IB2014/063782 WO2015022609A1 (en) | 2013-08-14 | 2014-08-07 | Combination therapy for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019045031A Division JP2019131570A (ja) | 2013-08-14 | 2019-03-12 | がんの治療のための組合せ療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016528246A JP2016528246A (ja) | 2016-09-15 |
| JP2016528246A5 true JP2016528246A5 (OSRAM) | 2017-09-14 |
Family
ID=51355593
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533973A Withdrawn JP2016528246A (ja) | 2013-08-14 | 2014-08-07 | がんの治療のための組合せ療法 |
| JP2019045031A Pending JP2019131570A (ja) | 2013-08-14 | 2019-03-12 | がんの治療のための組合せ療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019045031A Pending JP2019131570A (ja) | 2013-08-14 | 2019-03-12 | がんの治療のための組合せ療法 |
Country Status (20)
| Country | Link |
|---|---|
| US (9) | US20160184311A1 (OSRAM) |
| EP (2) | EP3033086B1 (OSRAM) |
| JP (2) | JP2016528246A (OSRAM) |
| KR (4) | KR20240160682A (OSRAM) |
| CN (2) | CN110368497B (OSRAM) |
| AU (3) | AU2014307633A1 (OSRAM) |
| BR (1) | BR112016002465B1 (OSRAM) |
| CA (1) | CA2918190C (OSRAM) |
| CY (1) | CY1124810T1 (OSRAM) |
| DK (1) | DK3033086T3 (OSRAM) |
| ES (1) | ES2900829T3 (OSRAM) |
| HR (1) | HRP20211879T1 (OSRAM) |
| HU (1) | HUE057061T2 (OSRAM) |
| LT (1) | LT3033086T (OSRAM) |
| MX (2) | MX384403B (OSRAM) |
| PL (1) | PL3033086T3 (OSRAM) |
| PT (1) | PT3033086T (OSRAM) |
| RU (1) | RU2680714C2 (OSRAM) |
| SI (1) | SI3033086T1 (OSRAM) |
| WO (1) | WO2015022609A1 (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2686840C1 (ru) * | 2015-06-04 | 2019-05-06 | Пфайзер Инк. | Твёрдые лекарственные формы палбоциклиба |
| CN105130992B (zh) * | 2015-07-16 | 2018-02-09 | 苏州大学 | 具有激酶抑制活性的含氮杂环化合物、制备方法和用途 |
| WO2017021177A1 (en) * | 2015-08-04 | 2017-02-09 | Universitat De Barcelona | Pharmaceutical combinations for use in the treatment of cancer |
| CN108348514A (zh) * | 2015-08-28 | 2018-07-31 | 诺华股份有限公司 | 含pi3k抑制剂alpelisib和cdk4/6抑制剂ribociclib的药物组合以及其在治疗/预防癌症中的应用 |
| JP2018525402A (ja) * | 2015-08-28 | 2018-09-06 | ノバルティス アーゲー | Ｐｉ３ｋ阻害剤のアルペリシブおよびｂ−ｒａｆ阻害剤のダブラフェニブを含む組合せ医薬、がんの治療または予防におけるそのような組合せの使用 |
| CA3239447A1 (en) * | 2016-01-11 | 2017-07-20 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
| CN107137409A (zh) * | 2016-03-01 | 2017-09-08 | 江苏恒瑞医药股份有限公司 | 一种cdk4/6抑制剂与雌激素受体拮抗剂联合在制备治疗乳腺癌的药物中的用途 |
| CN107137408A (zh) * | 2016-03-01 | 2017-09-08 | 江苏恒瑞医药股份有限公司 | 一种cdk4/6抑制剂与芳香化酶抑制剂联合在制备治疗乳腺癌的药物中的用途 |
| BR112018068512A2 (pt) * | 2016-03-15 | 2019-01-22 | Merrimack Pharmaceuticals Inc | métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3 |
| US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
| WO2018001270A1 (en) * | 2016-06-30 | 2018-01-04 | Noratech Pharmaceuticals, Inc. | Palbociclib prodrugs and composition thereof |
| WO2018017410A1 (en) | 2016-07-22 | 2018-01-25 | Eli Lilly And Company | Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer |
| US20190175598A1 (en) * | 2016-08-23 | 2019-06-13 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
| US11083722B2 (en) | 2017-03-16 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
| EP3434272A1 (en) * | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| AU2018311522A1 (en) * | 2017-08-03 | 2020-01-16 | Novartis Ag | Therapeutic combination of a third generation EGFR tyrosine kinase inhibitor and a cyclin D kinase inhibitor |
| US11179365B2 (en) | 2017-11-16 | 2021-11-23 | Novartis Ag | Pharmaceutical combination comprising LSZ102 and ribociclib |
| US10695333B2 (en) | 2017-12-01 | 2020-06-30 | Novartis Ag | Pharmaceutical combination comprising LSZ102 and alpelisib |
| CN112638869B (zh) | 2018-09-07 | 2025-04-25 | 赛诺菲 | 6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的盐及其制备方法 |
| CA3117666A1 (en) | 2018-10-26 | 2020-04-30 | Syndevrx, Inc. | Biomarkers of metap2 inhibitors and applications thereof |
| WO2021110122A1 (zh) * | 2019-12-05 | 2021-06-10 | 基石药业（苏州）有限公司 | Cdk4/6抑制剂的组合疗法 |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| WO2021231250A1 (en) * | 2020-05-12 | 2021-11-18 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
| US20240139208A1 (en) * | 2021-03-03 | 2024-05-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combined pharmaceutical composition containing cdk4/6 inhibitor and use thereof |
| CN117222411A (zh) * | 2021-03-24 | 2023-12-12 | 贝达药业股份有限公司 | 药物组合、包含其的试剂盒及其用途 |
| TW202304424A (zh) * | 2021-04-12 | 2023-02-01 | 法商賽諾菲公司 | 包含依維莫司和安森司群的組合 |
| TW202304425A (zh) * | 2021-04-12 | 2023-02-01 | 法商賽諾菲公司 | 包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合 |
| CN119215051A (zh) * | 2021-09-27 | 2024-12-31 | 正大天晴药业集团股份有限公司 | Cdk4/6抑制剂和芳香酶抑制剂的联用药物组合物 |
| KR102658209B1 (ko) * | 2021-10-05 | 2024-04-18 | 재단법인 아산사회복지재단 | Cdk 억제제 및 id2 활성화제를 포함하는 방광암의 예방 또는 치료용 약학 조성물 |
| WO2023091724A1 (en) * | 2021-11-18 | 2023-05-25 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| EP4440576A1 (en) * | 2021-12-02 | 2024-10-09 | Pfizer Inc. | Cdk4 inhibitor for the treatment of cancer |
| EP4618992A1 (en) * | 2022-11-17 | 2025-09-24 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| EP4626890A1 (en) | 2022-12-01 | 2025-10-08 | KRKA, d.d., Novo mesto | Ribociclib salts and formulations thereof |
| TW202440113A (zh) | 2023-03-27 | 2024-10-16 | 瑞士商諾華公司 | 治療早期乳癌之方法 |
| US20250319032A1 (en) | 2024-04-15 | 2025-10-16 | Novartis Ag | Pharmaceutical compositions of ribociclib |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749713A (en) | 1986-03-07 | 1988-06-07 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
| US4978672A (en) | 1986-03-07 | 1990-12-18 | Ciba-Geigy Corporation | Alpha-heterocyclc substituted tolunitriles |
| JP2710053B2 (ja) | 1988-07-05 | 1998-02-10 | スズキ株式会社 | 自動車の車体構造 |
| US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| US7196092B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| CN103110948A (zh) * | 2005-11-04 | 2013-05-22 | 惠氏公司 | mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合 |
| AU2006315632A1 (en) * | 2005-11-11 | 2007-05-24 | Pfizer, Inc. | Combinations and methods of using an immunomodulatory oligodeoxynucleotide |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2008009927A1 (en) * | 2006-07-18 | 2008-01-24 | Astrazeneca Ab | Use of fulvestrant and an aromatase inhibitor for treating breast cancer |
| BRPI0917791B1 (pt) | 2008-08-22 | 2022-03-22 | Novartis Ag | Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| WO2010104923A1 (en) * | 2009-03-11 | 2010-09-16 | Research Development Foundation | Low molecular weight cyclin e (lmw-e) as a biomarker for personalization of cancer therapies |
| WO2011010349A1 (ja) | 2009-07-23 | 2011-01-27 | 株式会社アドバンテスト | 試験装置 |
| UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| UY33227A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| MX2012011912A (es) * | 2010-04-13 | 2012-11-16 | Novartis Ag | Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer. |
| UY34072A (es) * | 2011-05-17 | 2013-01-03 | Novartis Ag | Derivados sustituidos de indol |
| CN103635189B (zh) | 2011-07-01 | 2016-05-04 | 诺华股份有限公司 | 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗 |
| US20210228529A1 (en) * | 2012-07-13 | 2021-07-29 | University Of Tennessee Research Foundation | Pharmaceutical compositions for treating breast cancers and methods of uses thereof |
| WO2014203129A1 (en) * | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
| US11179365B2 (en) * | 2017-11-16 | 2021-11-23 | Novartis Ag | Pharmaceutical combination comprising LSZ102 and ribociclib |
-
2014
- 2014-08-07 KR KR1020247036571A patent/KR20240160682A/ko active Pending
- 2014-08-07 CA CA2918190A patent/CA2918190C/en active Active
- 2014-08-07 WO PCT/IB2014/063782 patent/WO2015022609A1/en not_active Ceased
- 2014-08-07 BR BR112016002465-6A patent/BR112016002465B1/pt active IP Right Grant
- 2014-08-07 MX MX2020002150A patent/MX384403B/es unknown
- 2014-08-07 PL PL14752433T patent/PL3033086T3/pl unknown
- 2014-08-07 US US14/911,160 patent/US20160184311A1/en not_active Abandoned
- 2014-08-07 KR KR1020167003387A patent/KR102318306B1/ko active Active
- 2014-08-07 EP EP14752433.4A patent/EP3033086B1/en active Active
- 2014-08-07 KR KR1020217034188A patent/KR102529049B1/ko active Active
- 2014-08-07 RU RU2016108667A patent/RU2680714C2/ru active
- 2014-08-07 HR HRP20211879TT patent/HRP20211879T1/hr unknown
- 2014-08-07 ES ES14752433T patent/ES2900829T3/es active Active
- 2014-08-07 KR KR1020237014750A patent/KR102736746B1/ko active Active
- 2014-08-07 DK DK14752433.4T patent/DK3033086T3/da active
- 2014-08-07 CN CN201910784658.9A patent/CN110368497B/zh active Active
- 2014-08-07 MX MX2016001793A patent/MX378263B/es unknown
- 2014-08-07 AU AU2014307633A patent/AU2014307633A1/en not_active Abandoned
- 2014-08-07 SI SI201431926T patent/SI3033086T1/sl unknown
- 2014-08-07 PT PT147524334T patent/PT3033086T/pt unknown
- 2014-08-07 HU HUE14752433A patent/HUE057061T2/hu unknown
- 2014-08-07 LT LTEPPCT/IB2014/063782T patent/LT3033086T/lt unknown
- 2014-08-07 JP JP2016533973A patent/JP2016528246A/ja not_active Withdrawn
- 2014-08-07 EP EP21193408.8A patent/EP4005573A1/en active Pending
- 2014-08-07 CN CN201480056526.XA patent/CN105828822B/zh active Active
-
2017
- 2017-08-11 AU AU2017213541A patent/AU2017213541B2/en active Active
-
2018
- 2018-08-16 US US15/998,710 patent/US20190046533A1/en not_active Abandoned
-
2019
- 2019-03-12 JP JP2019045031A patent/JP2019131570A/ja active Pending
- 2019-04-17 AU AU2019202674A patent/AU2019202674B2/en active Active
-
2021
- 2021-10-18 US US17/504,177 patent/US20220193079A1/en not_active Abandoned
- 2021-12-15 CY CY20211101103T patent/CY1124810T1/el unknown
-
2023
- 2023-08-16 US US18/450,594 patent/US20230398121A1/en not_active Abandoned
- 2023-08-16 US US18/450,559 patent/US20230405011A1/en not_active Abandoned
- 2023-09-19 US US18/469,975 patent/US20240016808A1/en active Pending
- 2023-10-02 US US18/479,410 patent/US20240066034A1/en active Pending
-
2025
- 2025-01-28 US US19/039,174 patent/US20250170134A1/en not_active Abandoned
- 2025-01-28 US US19/039,164 patent/US20250177402A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016528246A5 (OSRAM) | ||
| RU2016108667A (ru) | Комбинированная терапия для лечения рака | |
| JP2011515397A5 (OSRAM) | ||
| JP2014533284A5 (OSRAM) | ||
| JP2016536286A5 (OSRAM) | ||
| JP2015500225A5 (OSRAM) | ||
| RU2014147105A (ru) | 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения | |
| JP2015520753A5 (OSRAM) | ||
| JP2015536964A5 (OSRAM) | ||
| JP2015512398A5 (OSRAM) | ||
| RU2021107754A (ru) | ТЕТРАГИДРО-1H-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА | |
| JP2015536986A5 (OSRAM) | ||
| JP2016528162A5 (OSRAM) | ||
| JP2016522202A5 (OSRAM) | ||
| JP2016536352A5 (OSRAM) | ||
| JP2015096544A5 (OSRAM) | ||
| JP2015529234A5 (OSRAM) | ||
| RU2016148887A (ru) | Пиридиновые соединения пладиенолида и способы применения | |
| MX2017011635A (es) | Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida. | |
| JP2015038155A5 (OSRAM) | ||
| JP2016515628A5 (OSRAM) | ||
| JP2017526662A5 (OSRAM) | ||
| RU2014101626A (ru) | Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты | |
| JP2019533651A5 (OSRAM) | ||
| JP2016529285A5 (OSRAM) |